Eisai has said it is "outraged" by the latest German health technology assessment (HTA) decision, which found no evidence of additional benefit for epilepsy drug Fycompa (perampanel). IQWiG's verdict is a blow to the company, which has already been through the German system once before.
IQWiG said that Eisai had failed to provide any relevant data for comparison with other epilepsy drugs as specified by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?